Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eptacog Alfa→

Eptacog Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
102786-61-8
Molecular formula
Not available
Molecular weight
50000 g/mol
Drug class
Recombinant activated human coagulation factor VIIa (rFVIIabypassing haemostatic agent)
Mechanism of action
Activated factor VII binds tissue factor and activates factor X and, on activated platelet surfaces, factor IX; this supports local thrombin generation and fibrin formation even when factor VIII or IX activity is inhibited or deficient.
Indications / reported uses
  • Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in defined patients with congenital haemophilia and factor VIII/IX inhibitors, acquired haemophilia, congenital factor VII deficiency or Glanzmann thrombasthenia with platelet-transfusion refractoriness; exact eligibility is product-specific

Sources: EMA NovoSeven EPAR · UK SmPC — NovoSeven · EMA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eptacog Alfa Environmental Risk Assessment (ERA) (the Eptacog Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.